Motor nerve damage is associated with anti-ganglioside antibodies in diabetes

Journal of the Peripheral Nervous System

Volumn 9, Issue 3, 2004, Pages 138-143

  Matà, Sabrina ^a   Betti, Elisabetta ^a   Masotti, Giulio ^a   Pinto, Francesco ^a   Lolli, Francesco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anti ganglioside antibodies; Diabetes; Nerve conduction studies; Peripheral neuropathy

Indexed keywords

GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GM1; GLYCOLIPID; GLYCOSYLATED HEMOGLOBIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; SULFATIDE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; ASSAY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ELECTROPHYSIOLOGY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MOTOR NERVE; MOTOR NERVE CONDUCTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

ACTION POTENTIALS; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIBODIES; DEMOGRAPHY; DIABETES COMPLICATIONS; DIABETES MELLITUS; ELECTROMYOGRAPHY; FEMALE; GANGLIOSIDES; HUMANS; IMMUNOGLOBULINS; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; NEURAL CONDUCTION;

EID: 4944226386     PISSN: 10859489     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1085-9489.2004.09303.x     Document Type: Article

References (24)

1. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force (1991). Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 41:617-618.
2. Cachia MJ, Peakman M, Zanone M, Watkins PJ, Vergani D (1997). Reproducibility and persistence of neural and adrenal autoantibodies in diabetic autonomic neuropathy. Diabet Med 14:461-465.
3. Cullum NA, Coleman JW, Casson IF, McLean WG (1991). Anti-bodies to tubulin and microtubule-associated proteins. A study in diabetes mellitus, systemic lupus erythematosus, and rheumatoid arthritis. Mol Chem Neuropathol 15:159-172.
4. Dyck PJ, Kratz KM, Lehman KA, Karnes JL, Melton LJ III, O'Brien PC, Litchy WJ, Windebank AJ, Smith BE, Low PA, et al. (1991). The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 41:799-807.
5. Ejskjaer N, Arif S, Dodds W, Zanone MM, Vergani D, Watkins PJ, Peakma M (1999). Prevalence of autoantibodies to autonomic nervous tissue structures in Type 1 diabetes mellitus. Diabet Med 16:544-549.
6. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997). Diabetes Care 20:1183-1197.
7. Hoeldtke RD, Bryner KD, Hobbs GR, Horvath GG, Riggs JE, Christie I, Ganser G, Marcovina SM, Lernmark A (2000). Antibodies to glutamic acid decarboxylase and peripheral nerve function in type 1 diabetes. J Clin Endocrinol Metab 85:3297-3308.
8. Jaeger C, Allendorfer J, Hatziagelaki E, Dyrberg T, Bergis KH, Federlin K, Bretzel RG (1997). Persistent GAD 65 antibodies in longstanding IDDM are not associated with residual beta-cell function, neuropathy or HLA-DR status. Horm Metab Res 29:510-515.
9. Milicevic Z, Newlon PG, Pittenger GL, Stansberry KB, Vinik AI (1997). Anti-ganglioside GM1 antibody and distal symmetric 'diabetic polyneuropathy' with dominant motor features. Diabetologia 40:1364-1365.
10. Morano S, Tiberti C, Cristina G, Sensi M, Cipriani R, Guidobaldi L, Torresi P, Medici F, Anastasi E, Di Mario U (1999). Autoimmune markers and neurological complications in non-insulin-dependent diabetes mellitus. Hum Immunol 60:848-854.
11. Negrin P, Zara G (1995). Conduction studies as prognostic parameters in the natural history of diabetic neuropathy: a long-term follow-up of 114 patients. Electromyogr Clin Neurophysiol 35:341-350.
12. Rabinowe SL, Brown FM, Watts M, Kadrofske MM, Vinik AI (1989). Anti-sympathetic ganglia antibodies and postural blood pressure in IDDM subjects of varying duration and patients at high risk of developing IDDM. Diabetes Care 12:1-6.
13. Roll U, Nuber A, Schroder A, Gerlach E, Janka HU, Ziegler AG (1995). No association of antibodies to glutamic acid decarboxylase and diabetic complications in patients with IDDM. Diabetes Care 18:210-215.
14. van Schaik IN, Bossuyt PM, Brand A, Vermeulen M (1995). Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis. Neurology 45:1570-1577.
15. Shigeta H, Yamaguchi M, Nakano K, Obayashi H, Takemura R, Fukui M, Fujii M, Yoshimor K, Hasegawa G, Nakamura N, Kitagawa Y, Kondo M (1997). Serum autoantibodies against sulfatide and phospholipid in NIDDM patients with diabetic neuropathy. Diabetes Care 20:1896-1899.
16. Sundkvist G, Lind P, Bergstrom B, Lilja B, Rabinowe SL (1991). Autonomic nerve antibodies and autonomic nerve function in type 1 and type 2 diabetic patients. J Intern Med 229:505-510.
17. Sundkvist G, Velloso LA, Kampe O, Rabinowe SL, Ivarsson SA, Lilja B, Karlsson FA (1994). Glutamic acid decarboxylase antibodies, autonomic nerve antibodies and autonomic neuropathy in diabetic patients. Diabetologia 37:293-299.
18. Tiberti C, Dotta F, Anastasi E, Torresi P, Multari G, Vecci E, Andreani D, Di Mario U (1995). Anti-ganglioside antibodies in new onset type 1 diabetic patients and high risk subjects. Autoimmunity 22:43-48.
19. Tjissen P (1985). Practice and Theory of Enzyme Immunoassay. In: Burbon RH, van Knippenberg PH (Eds.), Laboratory Techniques in Biochemistry and Molecular Biology, Vol. 15. Elsevier, Amsterdam: pp 1-549.
20. Vinik AI, Leichter SB, Pittenger GL, Stansberry KB, Holland MT, Powers AC, Suwanwalaikorn S (1995). Phospholipid and glutamic acid decarboxylase autoantibodies in diabetic neuropathy. Diabetes Care 18:1225-1232.
21. Weber F, Rudel R, Aulkemeyer P, Brinkmeier H (2000). Anti-GM1 antibodies block neuronal voltage-gated sodium channels. Muscle Nerve 23:1414-1420.
22. Willison HJ, Yuki N (2002). Peripheral neuropathies and anti-glycolipid antibodies. Brain 125:2591-2625.
23. Zanone MM, Petersen JS, Peakman M, Mathias CJ, Watkins PJ, Dyrberg T, Vergani D (1994). High prevalence of autoantibodies to glutamic acid decarboxylase in long-standing IDDM is not a marker of symptomatic autonomic neuropathy. Diabetes 43:1146-1151.
24. Zanone MM, Petersen JS, Vergani D, Peakman M (1997). Expression of glutamic acid decarboxylase in nervous tissue structures targeted by autoantibodies in patients with diabetic autonomic neuropathy. J Neuroimmunol 78:1-7.